Literature DB >> 16763805

Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Rong-Ping Guo1, Chong Zhong, Ming Shi, Chang-Qing Zhang, Wei Wei, Ya-Qi Zhang, Jin-Qing Li.   

Abstract

PURPOSE: Whereas some studies have indicated that the prognosis of hepatocellular carcinoma (HCC) was correlated to some apoptosis and angiogenesis factors: p53, survivin, matrix metalloproteinases (MMPs, including MMP-2 and MMP-9) and vascular endothelial growth factor (VEGF), other studies have failed to confirm this. The aim of the present study is to investigate the expression of p53, survivin, MMPs and VEGF in HCC and the relationship between these factors and the prognosis of HCC patients.
METHODS: The expression of p53, survivin, MMP-2, MMP-9 and VEGF was measured by immunohistochemical assays in the liver resection specimens of 90 patients with HCC.
RESULTS: The positive rate of p53, survivin, MMP-2, MMP-9 and VEGF was 33.3, 51.1, 60.0, 37.8 and 76.7%, respectively. The expression of MMP-2, MMP-9 and VEGF was correlated to the recurrence of HCC patients, respectively (P < 0.01). No correlation was found between the expression of apoptosis factors (p53 and survivin) and the recurrence of HCC patients, respectively (P > 0.05). The positive correlations were found between MMP-2 and VEGF (r = 0.32, P < 0.01), MMP-9 and VEGF (r = 0.24, P < 0.05). Significant differences of disease-free survival rates occurred among subgroups according to the expression of MMP-2, MMP-9 and VEGF (P < 0.01). Multivariate analysis revealed that macroscopically disseminated nodules, tumor micrometastasis, high serum alpha-fetoprotein level, positive expression of MMP-9 and VEGF were independent recurrence risk factors.
CONCLUSIONS: Our investigation revealed that p53 and survivin could not estimate the prognosis of HCC patients. Angiogenesis factors (MMPs and VEGF) positively correlated to the prognosis of HCC patients. The expression of MMPs and VEGF in HCC tissues could be regarded as a valuable indicator in estimating the prognosis of HCC patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763805     DOI: 10.1007/s00432-006-0097-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

1.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma.

Authors:  Kazuaki Nakanishi; Michiie Sakamoto; Susumu Yamasaki; Satoru Todo; Setsuo Hirohashi
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

4.  Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation.

Authors:  Rajesh Kannangai; Jianzhou Wang; Qiong Z Liu; Fikret Sahin; Michael Torbenson
Journal:  Int J Gastrointest Cancer       Date:  2005

5.  Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation.

Authors:  S Tanaka; Y Toh; E Adachi; T Matsumata; R Mori; K Sugimachi
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

6.  Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.

Authors:  M Määttä; Y Soini; A Liakka; H Autio-Harmainen
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

7.  Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors.

Authors:  G G Garzetti; A Ciavattini; G Lucarini; A Pugnaloni; M De Nictolis; S Amati; C Romanini; G Biagini
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

8.  Investigation of resected multinodular hepatocellular carcinoma: assessment of unicentric or multicentric genesis from histological and prognostic viewpoint.

Authors:  S Nakano; J Haratake; K Okamoto; S Takeda
Journal:  Am J Gastroenterol       Date:  1994-02       Impact factor: 10.864

9.  A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma.

Authors:  Y Ishii; Y Nakasato; S Kobayashi; Y Yamazaki; T Aoki
Journal:  J Exp Clin Cancer Res       Date:  2003-09

10.  Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma.

Authors:  Soichiro Morinaga; Yoshiyasu Nakamura; Naoki Ishiwa; Takaki Yoshikawa; Yoshikazu Noguchi; Yuji Yamamoto; Yasushi Rino; Toshio Imada; Yoshinori Takanashi; Makoto Akaike; Yukio Sugimasa; Shoji Takemiya
Journal:  Oncol Rep       Date:  2004-12       Impact factor: 3.906

View more
  27 in total

1.  Effects of dietary fat on spontaneous metastasis of Lewis lung carcinoma in mice.

Authors:  Lin Yan; Lana C DeMars
Journal:  Clin Exp Metastasis       Date:  2010-08-10       Impact factor: 5.150

Review 2.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

3.  Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Yasuhide Ikenaka; Kosuke Kaji; Yusaku Shirai; Yosuke Aihara; Junichi Yamao; Masahisa Toyohara; Akira Mitoro; Masayoshi Sawai; Motoyuki Yoshida; Chie Morioka; Masao Fujimoto; Masahito Uemura; Hideto Kawaratani; Tatsuhiro Tsujimoto; Hiroshi Fukui
Journal:  Oncol Lett       Date:  2010-10-05       Impact factor: 2.967

4.  TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Jun Xue
Journal:  Tumour Biol       Date:  2014-02

Review 5.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

6.  Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

7.  Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Yosuke Aihara; Akitoshi Douhara; Hideto Kawaratani; Norihisa Nishimura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2013-11-07       Impact factor: 7.527

8.  A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.

Authors:  Chong Zhong; Rong-ping Guo; Jin-qing Li; Ming Shi; Wei Wei; Min-shan Chen; Ya-qi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-01       Impact factor: 4.553

Review 9.  Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful?

Authors:  Natale D'Alessandro; Paola Poma; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

10.  Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma.

Authors:  Claudia Augello; Luca Caruso; Marco Maggioni; Matteo Donadon; Marco Montorsi; Roberto Santambrogio; Guido Torzilli; Valentina Vaira; Caterina Pellegrini; Massimo Roncalli; Guido Coggi; Silvano Bosari
Journal:  BMC Cancer       Date:  2009-04-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.